Felipe Lauand
Sanofi (France)(FR)
Publications by Year
Research Areas
Diabetes Treatment and Management, Diabetes Management and Research, Diabetes and associated disorders, Metabolism, Diabetes, and Cancer, Pancreatic function and diabetes
Most-Cited Works
- → The SAGE study: Global observational analysis of glycaemic control, hypoglycaemia and diabetes management in T1DM(2020)73 cited
- → Glucocorticoid modulation of atrial natriuretic peptide, oxytocin, vasopressin and Fos expression in response to osmotic, angiotensinergic and cholinergic stimulation(2007)47 cited
- → Linagliptin: farmacology, efficacy and safety in type 2 diabetes treatment(2013)39 cited
- → Differential glycaemic control with basal insulin glargine 300 U/mL versus degludec 100 U/mL according to kidney function in type 2 diabetes: A subanalysis from the BRIGHT trial(2020)30 cited
- → Lower risk of severe hypoglycaemia with insulin glargine 300 U/ mL versus glargine 100 U/ mL in participants with type 1 diabetes: A meta‐analysis of 6‐month phase 3 clinical trials(2020)24 cited
- → Improvements in Glycemic Outcomes in 4738 Children, Adolescents, and Adults with Type 1 Diabetes Initiating a Tubeless Insulin Management System(2023)15 cited
- → The efficacy and safety of iGlarLixi versus IDegAsp in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli‐D randomized controlled trial(2024)14 cited
- → iGlarLixi provides a higher derived time‐in‐range versus insulin glargine 100 U / mL or lixisenatide in Asian Pacific people with type 2 diabetes: A post hoc analysis(2023)6 cited
- Efeito da hipovolemia sobre a cicatrização de anastomoses colônicas: estudo experimental em ratos(2004)
- → 131-LB: Differences in HbA1c Reduction between Insulin Glargine 300 U/mL (Gla-300) and Insulin Degludec 100 U/mL (IDeg-100) in Adults ≥70 Years of Age with T2DM in the BRIGHT Trial(2019)5 cited